Results 111 to 120 of about 1,100,787 (194)

Invasive fungal infections after Bruton tyrosine kinase inhibitor treatment: a systematic review and meta-analysis. [PDF]

Blood Adv
Srisurapanont K, Meejun T, Manothummetha K, Li LX, Baddley JW, Schulz CA, Dioverti-Prono MV, Zhang SX, Avery RK, Kates OS, Permpalung N.   +10 more
europepmc   +1 more source

Efficacy and Safety of Bruton Tyrosine Kinase Inhibitor Monotherapy Compared with Combination Therapy for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Systematic Review and Meta-Analysis. [PDF]

Cancers (Basel), 2023
Nguyen TT, Nhu NT, Tran VK, Nguyen TTH, Lin CF.   +4 more
europepmc   +1 more source

Bruton Tyrosine Kinase Inhibitor Ibrutinib and Pericardial Tamponade: A Case Report. [PDF]

Cureus
Baptista M, Soares M, Lima R, Ferreira C, Gregório T.   +4 more
europepmc   +1 more source

Protocol for a multicentre randomised controlled trial examining the effects of temporarily pausing Bruton tyrosine kinase inhibitor therapy to coincide with SARS-CoV-2 vaccination and its impact on immune responses in patients with chronic lymphocytic leukaemia. [PDF]

BMJ Open, 2023
Barber VS, Peckham N, Duley L, Francis A, Abhishek A, Moss P, Cook JA, Parry HM.   +7 more
europepmc   +1 more source

Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor. [PDF]

J Clin Oncol
Eyre TA, Song Y, Hermine O, Shuang Y, Jurczak W, Farias JS, Mahuad C, Özcan M, Jachimowicz RD, Chen T, Ivanova E, Li X, Man G, Bourquelot P, Vezan R, Wang M.   +15 more
europepmc   +1 more source

Long-term outcomes and treatment patterns in Waldenström macroglobulinemia patients who discontinue Bruton tyrosine kinase inhibitor (BTKi) therapy. [PDF]

Blood Cancer J
Chohan KL, Gensini L, Seif S, Sun X, Feng L, Becnel MR, Gaballa MM, Lee HC, Pasvolsky O, Patel KK, Ye JC, Weber DM, Orlowski RZ, Thomas SK.   +13 more
europepmc   +1 more source

Treatment patterns in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma post covalent Bruton tyrosine kinase inhibitor treatment: a Japanese claims database study. [PDF]

J Clin Exp Hematop, 2023
Maruyama D, Wang C, Tanizawa Y, Cai Z, Huang Y, Tajimi M, Kusumoto S.   +6 more
europepmc   +1 more source

Real-world efficacy of Bruton tyrosine kinase inhibitor based maintenance therapy in diffuse large B-cell lymphoma: a multicenter retrospective cohort study with external historical control. [PDF]

Cancer Biol Ther
Lyu LW, Yao N, Liu ZX, Wang YY, Li J, Zhou HB, Li LH, Li ZL, Wang L.   +8 more
europepmc   +1 more source

Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study. [PDF]

Br J Haematol, 2023
Hess G, Dreyling M, Oberic L, Gine E, Zinzani PL, Linton K, Vilmar A, Jerkeman M, Chen JMH, Ohler A, Stilgenbauer S, Thieblemont C, Lambert J, Zilioli VR, Sancho JM, Jiménez-Ubieto A, Fischer L, Eyre TA, Keeping S, Park JE, Wu JJ, Siddiqi R, Reitan J, Wade S, Salles G.   +24 more
europepmc   +1 more source

A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia. [PDF]

Clin Cancer Res, 2021
An G, Zhou D, Cheng S, Zhou K, Li J, Zhou J, Xie L, Jin J, Zhong L, Yan L, Guo H, Du C, Zhong J, Yu Y, Wu B, Qiu L.   +15 more
europepmc   +1 more source